Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study-Reference-Cited by-同舟云学术

Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study

Published:2023-06-05 Issue:5 Volume:17 Page:1150-1161
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Wong Yu Jun,Tran Sally,Huang Chung-Feng,Hsu Yao-Chun,Preda Carmen,Toyoda Hidenori,Liu Joanne,Jun Dae Won,Landis Charles,Huang Daniel Q.,Gila Andrei,Negoita Livia,Yasuda Satoshi,Tseng Cheng-Hao,Tsai Pei-Chien,Uojima Haruki,Nozaki Akito,Chuma Makoto,Atsukawa Masanori,Ishigami Masatoshi,Itokawa Norio,Iio Etsuko,Lam Carla Pui-Mei,Watanabe Tsunamasa,Asai Akira,Yokohama Keisuke,Abe Hiroshi,Enomoto Masaru,Kawada Norifumi,Tamori Akihiro,Lee Dong Hyun,Jun Mi Jung,Do Son,Vo Dang K. H.,Liu Li,Li Junyi,Ji Fanpu,Wang Wenjun,Li Yu,Wang Xiaozhong,Guo Fen,Xu Qiang,Jing Liang,Ye Qing,Pan Hongying,Zhang JiaJie,Wen Xie,Wang Qi,Ren Hong,Cai Dachuan,Shang Jia,Liu Junping,Lu Chengzheng,Zang Wenqian,Li Jia,Niu Junqi,Zhang Mingyuan,Wu Chao,Huang Rui,Maeda Mayumi,Nakanishi Akiko,Yeh Ming-Lun,Chuang Wan-Long,Huang Jee-Fu,Dai ChiaYen,Ishikawa Toru,Takaguchi Koichi,Senoh Tomonori,Trinh Huy N.,Takahashi Hirokazu,Eguchi Yuichiro,Quek Sabrina Xin Zi,Haga Hiroaki,Ogawa Eiichi,Wong Grace,Buti Maria,Fukunishi Shinya,Ueno Yoshiyuki,Yuen Man-Fung,Tanaka Yasuhito,Lim Seng Gee,Cheung Ramsey,Yu Ming-Lung,Nguyen Mindie H.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-023-10547-4.pdf

Reference22 articles.

1. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022;7(5):396–415

2. Kiser JJ. Safety of hepatitis C viral protease inhibitors in compensated cirrhotic: lingering concerns put to rest? Clin Infect Dis 2019;69(10):1665–1666

3. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and Assessed on 1 Mar 2023

4. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67(10):1477–1492

5. EASL Governing Board representative. Panel members: EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol 2020;73(5):1170–1218

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices;Pharmacological Reports;2024-08-20

2. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review;Expert Opinion on Pharmacotherapy;2024-08-12

3. Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis;eClinicalMedicine;2024-08

4. Pharmacologic Treatment of Portal Hypertension;Clinics in Liver Disease;2024-08

5. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals;Expert Opinion on Pharmacotherapy;2024-05-02